《新股表现》锦欣生殖(01951.HK)半日收9.37元高上市价9.7%
锦欣生殖(01951.HK)暗盘高开逾12%,最多涨17.1%高见10元,收9.83元,高上市价15.1%;该股首挂高开15.9%报9.9元,最多涨25.1%至10.68元遇阻,曾回顺至9.12元,半日收9.37元,较上市价8.54元,高9.7%,半日成交1.92亿股,涉资18.99亿元。
锦欣生殖是中美领先的辅助生殖(人工授孕)服务供应商。是次上市共发售逾3.57亿股,并已引入高瓴、汇桥、奥博及Cormorant为基石投资者,合共认购1.3769亿股;10%公开发售获98.26倍超购,已启动回拨机制占比增至40%,认购一手中签率65%;股份以招股范围(7.76-8.54元)上限定价,料集资净额28.081亿元,主要用作拓展及升级内地网络现有辅助生殖医疗机构和招聘医疗专业人士、用作潜在收缩目前并无业务内地省份的额外辅助生殖医疗机构、收购辅助生殖服务提供商与沿辅助生殖服务服务链的业务、投资研发,以及提高中国和美国的品牌知名度及整体辅助生殖服务认知度等。上市联席保荐人分别为大摩和中信里昂。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.